Literature DB >> 21889725

New hormonal therapies for castration-resistant prostate cancer.

Elahe A Mostaghel1, Stephen Plymate.   

Abstract

Continued activation of the androgen receptor (AR) axis despite castration remains a critical force in the development of castration-resistant prostate cancer (CRPC). Therapeutic strategies designed to more effectively ablate tumoral androgen activity are required to improve clinical efficacy and prevent disease progression. Tumor-based alterations in expression and activity of the AR and in steroidogenic pathways mediating ligand generation facilitate the development of CRPC. This article reviews AR and ligand-dependent mechanisms underlying CRPC progression and the status of novel hormonal therapies targeting the AR axis that are currently in clinical and preclinical development.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21889725      PMCID： PMC3167094          DOI： 10.1016/j.ecl.2011.05.013

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.741


  68 in total

Review 1.  Interaction of IGF signaling and the androgen receptor in prostate cancer progression.

Authors:  Jennifer D Wu; Kathy Haugk; Libby Woodke; Peter Nelson; Ilsa Coleman; Stephen R Plymate
Journal:  J Cell Biochem       Date:  2006-10-01       Impact factor: 4.429

2.  Persistent intraprostatic androgen concentrations after medical castration in healthy men.

Authors:  Stephanie T Page; Daniel W Lin; Elahe A Mostaghel; David L Hess; Lawrence D True; John K Amory; Peter S Nelson; Alvin M Matsumoto; William J Bremner
Journal:  J Clin Endocrinol Metab       Date:  2006-08-01       Impact factor: 5.958

3.  Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

Authors:  Deborah L Marrocco; Wayne D Tilley; Tina Bianco-Miotto; Andreas Evdokiou; Howard I Scher; Richard A Rifkind; Paul A Marks; Victoria M Richon; Lisa M Butler
Journal:  Mol Cancer Ther       Date:  2007-01-11       Impact factor: 6.261

4.  Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

Authors:  Charles J Ryan; Susan Halabi; San-San Ou; Nicholas J Vogelzang; Philip Kantoff; Eric J Small
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

Review 5.  Combinatorial androgen receptor targeted therapy for prostate cancer.

Authors:  P Singh; A Uzgare; I Litvinov; S R Denmeade; J T Isaacs
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

6.  Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer.

Authors:  David R Bauman; Stephan Steckelbroeck; Donna M Peehl; Trevor M Penning
Journal:  Endocrinology       Date:  2006-09-07       Impact factor: 4.736

Review 7.  Androgen receptor coregulators and their involvement in the development and progression of prostate cancer.

Authors:  Renée Chmelar; Grant Buchanan; Eleanor F Need; Wayne Tilley; Norman M Greenberg
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

8.  An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.

Authors:  Michael C Byrns; Stephan Steckelbroeck; Trevor M Penning
Journal:  Biochem Pharmacol       Date:  2007-09-14       Impact factor: 5.858

9.  Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.

Authors:  Qing Ji; Lilly Chang; Frank Z Stanczyk; Murad Ookhtens; Andy Sherrod; Andrew Stolz
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701
View more
  10 in total

Review 1.  Allosteric alterations in the androgen receptor and activity in prostate cancer.

Authors:  Takuma Uo; Stephen R Plymate; Cynthia C Sprenger
Journal:  Endocr Relat Cancer       Date:  2017-09       Impact factor: 5.678

Review 2.  The link between androgen receptor splice variants and castration-resistant prostate cancer.

Authors:  Cynthia C T Sprenger; Stephen R Plymate
Journal:  Horm Cancer       Date:  2014-05-06       Impact factor: 3.869

Review 3.  Abiraterone in prostate cancer: a new angle to an old problem.

Authors:  Mark N Stein; Susan Goodin; Robert S Dipaola
Journal:  Clin Cancer Res       Date:  2012-03-26       Impact factor: 12.531

4.  Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.

Authors:  Daniel Tamae; Michael Byrns; Brett Marck; Elahe A Mostaghel; Peter S Nelson; Paul Lange; Daniel Lin; Mary-Ellen Taplin; Steven Balk; William Ellis; Larry True; Robert Vessella; Bruce Montgomery; Ian A Blair; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2013-07-10       Impact factor: 4.292

5.  Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

Authors:  James P Dean; Cynthia C Sprenger; Junxiang Wan; Kathleen Haugk; William J Ellis; Daniel W Lin; John M Corman; Bruce L Dalkin; Elahe Mostaghel; Peter S Nelson; Pinchas Cohen; Bruce Montgomery; Stephen R Plymate
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

Review 6.  Androgen receptor antagonists in castration-resistant prostate cancer.

Authors:  Dana Rathkopf; Howard I Scher
Journal:  Cancer J       Date:  2013 Jan-Feb       Impact factor: 3.360

7.  Metformin targets c-MYC oncogene to prevent prostate cancer.

Authors:  Tunde Akinyeke; Satoko Matsumura; Xinying Wang; Yingjie Wu; Eric D Schalfer; Anjana Saxena; Wenbo Yan; Susan K Logan; Xin Li
Journal:  Carcinogenesis       Date:  2013-10-15       Impact factor: 4.944

Review 8.  Insights into Chemoresistance of Prostate Cancer.

Authors:  Wei Zhang; Yan Meng; Na Liu; Xiao-Fei Wen; Tao Yang
Journal:  Int J Biol Sci       Date:  2015-08-01       Impact factor: 6.580

9.  Targeting cell cycle and hormone receptor pathways in cancer.

Authors:  C E S Comstock; M A Augello; J F Goodwin; R de Leeuw; M J Schiewer; W F Ostrander; R A Burkhart; A K McClendon; P A McCue; E J Trabulsi; C D Lallas; L G Gomella; M M Centenera; J R Brody; L M Butler; W D Tilley; K E Knudsen
Journal:  Oncogene       Date:  2013-05-27       Impact factor: 9.867

10.  Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.

Authors:  Barbara Kahn; Joanne Collazo; Natasha Kyprianou
Journal:  Int J Biol Sci       Date:  2014-06-01       Impact factor: 6.580
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.